Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases

Oncotarget

Volumn 8, Issue 39, 2017, Pages 66117-66127

  Shady, Waleed ^a   Petre, Elena N ^a   Vakiani, Efsevia ^a   Ziv, Etay ^a   Gonen, Mithat ^a   Brown, Karen T ^a   Kemeny, Nancy E ^a   Solomon, Stephen B ^a   Solit, David B ^a   Sofocleous, Constantinos T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Colorectal liver metastases; Kras mutation; Oncologic outcomes; Percutaneous radiofrequency ablation

Indexed keywords

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; EXON; GENE MUTATION; HUMAN; LIVER METASTASIS; LOCAL TUMOR PROGRESSION; LUNG METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE K RAS; OVERALL SURVIVAL; PERITONEUM METASTASIS; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 85030087002     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.19806     Document Type: Article

References (33)

1. Van Tilborg AA, Meijerink MR, Sietses C, Van Waesberghe JH, Mackintosh MO, Meijer S, Van Kuijk C, Van Den Tol P. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol. 2011; 84:556-65.
2. Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, Kylstra JW. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first-and second-line management. Cancer J. 2006; 12:318-26.
3. Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012; 265:958-68.
4. Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, Alago W, Durack JC, Maybody M, Brody LA, Siegelbaum RH, D'Angelica MI, Jarnagin WR, et al. Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes-A 10-year Experience at a Single Center. Radiology. 2016; 278:601-11.
5. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005; 23:1358-64.
6. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Annals of surgery. 2004; 239:818-825.
7. Sofocleous CT, Petre EN, Gonen M, Brown KT, Solomon SB, Covey AM, Alago W, Brody LA, Thornton RH, D'Angelica M, Fong Y, Kemeny NE. CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Interv Radiol. 2011; 22:755-61.
8. Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, Alago W, Durack JC, Maybody M, Brody LA, Siegelbaum RH, D'Angelica MI, Jarnagin WR, et al. Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes-A 10-year Experience at a Single Center. Radiology. 2016; 278:601-11.
9. Sotirchos VS, Petrovic LM, Gönen M, Klimstra DS, Do RK, Petre EN, Garcia AR, Barlas A, Erinjeri JP, Brown KT, Covey AM, Alago W, Brody LA, et al. Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome. Radiology. 2016; 280:949-59.
10. Sofocleous CT, Nascimento RG, Petrovic LM, Klimstra DS, Gonen M, Brown KT, Brody LA, Covey AM, Thornton RH, Fong Y, Solomon SB, Schwartz LH, DeMatteo RP, Getrajdman GI. Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology. 2008; 249:364-74.
11. Sofocleous CT, Garg S, Petrovic LM, Gonen M, Petre EN, Klimstra DS, Solomon SB, Brown KT, Brody LA, Covey AM, Dematteo RP, Schwartz L, Kemeny NE. Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Ann Surg Oncol. 2012; 19:4262-69.
12. Pawlik TM, Choti MA. Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. Curr Oncol Rep. 2007; 9:193-201.
13. Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA Jr, Donehower RC, Hirose K, Ahuja N, Pawlik TM, Choti MA. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013; 119:4137-44.
14. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013; 258:619-626.
15. Kemeny NE, Chou JF, Capanu M, Gewirtz AN, Cercek A, Kingham TP, Jarnagin WR, Fong YC, DeMatteo RP, Allen PJ, Shia J, Ang C, Vakiani E, D'Angelica MI. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer. 2014; 120:3965-71.
16. Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, Kemeny N, Paty PB. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010; 17:572-78.
17. Shindoh J, Nishioka Y, Yoshioka R, Sugawara T, Sakamoto Y, Hasegawa K, Hashimoto M, Kokudo N. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion. Ann Surg Oncol. 2016; 23:1890-96.
18. Margonis GA, Spolverato G, Kim Y, Karagkounis G, Choti MA, Pawlik TM. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases. Ann Surg Oncol. 2015; 22:4158-65.
19. Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015; 102:1175-83.
20. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009; 27:5931-37.
21. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29:2011-19.
22. Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, Kemeny N. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2015; 121:1195-203.
23. Odisio BC, Yamashita S, Huang SY, Harmoush S, Kopetz SE, Ahrar K, Shin Chun Y, Conrad C, Aloia TA, Gupta S, Hicks ME, Vauthey JN. Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg. 2017; 104:760-68.
24. Brudvik KW, Mise Y, Chung MH, Chun YS, Kopetz SE, Passot G, Conrad C, Maru DM, Aloia TA, Vauthey JN. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol. 2016; 23:2635-43.
25. Pinheiro RS, Herman P, Lupinacci RM, Lai Q, Mello ES, Coelho FF, Perini MV, Pugliese V, Andraus W, Cecconello I, D'Albuquerque LC. Tumor growth pattern as predictor of colorectal liver metastasis recurrence. Am J Surg. 2014; 207:493-98.
26. Wang X, Sofocleous CT, Erinjeri JP, Petre EN, Gonen M, Do KG, Brown KT, Covey AM, Brody LA, Alago W, Thornton RH, Kemeny NE, Solomon SB. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol. 2013; 36:166-75.
27. Ghosh A, Lai C, McDonald S, Suraweera N, Sengupta N, Propper D, Dorudi S, Silver A. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53. Exp Mol Pathol. 2013; 94:103-08.
28. Thompson SM, Callstrom MR, Jondal DE, Butters KA, Knudsen BE, Anderson JL, Lien KR, Sutor SL, Lee JS, Thorgeirsson SS, Grande JP, Roberts LR, Woodrum DA. Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress. PLoS One. 2016; 11:e0162634.
29. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A, Paty P, Chan TA, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012; 30:2956-62.
30. Ryan ER, Sofocleous CT, Schöder H, Carrasquillo JA, Nehmeh S, Larson SM, Thornton R, Siegelbaum RH, Erinjeri JP, Solomon SB. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology. 2013; 268:288-95.
31. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baère T, Dodd GD 3rd, Dupuy DE, Gervais DA, Gianfelice D, et al. Imageguided tumor ablation: standardization of terminology and reporting criteria a 10-year update. J Vasc Interv Radiol. 2014; 25:1691-1705 e1694.
32. North DA, Groeschl RT, Sindram D, Martinie JB, Iannitti DA, Bloomston M, Schmidt C, Rilling WS, Gamblin TC, Martin RC. Microwave ablation for hepatic malignancies: a call for standard reporting and outcomes. Am J Surg. 2014; 208:284-94.
33. Gönen M, Panageas KS, Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology. 2001; 221:763-67.